Please login to the form below

Not currently logged in
Email:
Password:

Shire picks Bayer's Flemming Ornskov as new head

He will succeed Angus Russell who is retiring next year

Shire Flemming OrnskovAngus Russell is stepping down as chief executive of the Dublin-based specialty pharmaceutical company Shire next year.

His replacement will be Flemming Ornskov, who is currently chief marketing office and global head of strategic marketing (general and specialty medicine) at Bayer.

Ornskov will join the company on January 2, 2013, as chief executive designate, spend time with all three Shire businesses and will have a special focus initially on the specialty pharmaceuticals business.

He will be based at Shire's US offices outside Philadelphia, during this period, following after which he will become CEO on April 30, 2013.

Flemming Ornskov said: “Shire stands out in the industry. I'm motivated and inspired by the company's vision and excited to bring the combination of my medical, multi-national and entrepreneurial business background to lead Shire to the next phase of its development.”

Prior to his time at Bayer, Ornskov was global president, pharmaceuticals and OTC at Bausch & Lomb. Before this he served as CEO at both Lifecycle Pharma and US biotech Ikaria, and worked at Merck & Co and Novartis.

His selection as CEO came as part of Shire's search for a new president for its specialty pharmaceuticals business after the resignation in April of Michael Kola. A process the company intended to yield a potential successor for Angus Russell.

Russell will retire in 2013 after 13 years with Shire and a full 32 years of working in the pharmaceutical industry.

Shire chair Matthew Emmens said: “Angus led the company through a period of extraordinary growth and was instrumental in establishing a winning strategy and a powerful and compelling culture. We wish him and his family well in his retirement.”

26th October 2012

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Litmus MME

LITMUS places the development of strong physician relationships at the centre of every program and has established a new standard...

Latest intelligence

When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....
Forecasting for Licensed Compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharmaceutical forecasting...

Infographics